Compare Cytokinetics Inc (CYTK) vs General Motors Company (GM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs General Motors Company — how do they compare? Cytokinetics Inc trades at $82.48 (market cap $11.12B), while General Motors Company trades at $77.21 (market cap $69.31B). The key difference: General Motors Company is far larger — about 6.2× Cytokinetics Inc's market cap, and General Motors Company pays a 0.94% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | GM | |
|---|---|---|
Market Cap | $11.12B | $69.31B |
Sector | Technology | Consumer Cyclical |
52-Week High | $87.26 | $86.38 |
52-Week Low | $33.23 | $48.89 |
Enterprise Value | $11.59B | $172.65B |
Dividend Yield | — | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
General Motors (GM) trades at $76.72, down 1.45% on the day, with a bearish technical signal from moving averages. The company shows strong cash flow from operations at $26.87B for 2025 and has beaten earnings estimates for three consecutive quarters. Recent news highlights GM's strategic pivot into energy and domestic manufacturing expansion, supported by a 63% analyst buy rating. Valuation metrics include a P/E of 28 and P/S of 0.4, indicating potential value relative to sales.
GM's outlook is mixed: solid cash generation and analyst optimism (consensus target $102) contrast with declining net margins (1.38% in 2025) and rising debt-to-asset ratios (46.79% in 2024). Risks include competitive pressures and macroeconomic headwinds, but the stock offers upside if margin improvements and energy initiatives materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
